Journals / Balkan Medical Journal / 2022 / Cilt: 39 - Sayı: 4

Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma

Pages
246–254
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids.
📊
Key Findings & Data:Aims: To analyze the predictive value of miR-16-5p, miR-29c-3p, miR-31-5p, miR-125a-5p, miR-320a, miR-484 and miR-532-5p expressions for diagnosis, prognosis and response to treatment in patients with MPM.
💡
Conclusion & Impact:In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids. As in various cancers, their role in the diagnosis, prognosis, and treatment of patients with malignant pleural mesothelioma (MPM) may be important. Aims: To analyze the predictive value of miR-16-5p, miR-29c-3p, miR-31-5p, miR-125a-5p, miR-320a, miR-484 and miR-532-5p expressions for diagnosis, prognosis and response to treatment in patients with MPM. Study Design: Prospective case-control study. Methods: In the first phase of the study, blood samples were collected from 101 MPM patients before chemotherapy and from 24 healthy donors (HDs). In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined. A quantitative real-time polymerase chain reaction was undertaken to detect the miRNA expression levels. The miRNA expression profiles of MPM patients were compared with those of HDs. The associations between the expression levels of miRNAs and prognosis and response to treatment were then evaluated. Results: All miRNAs, except miR-31-5p, were expressed differently in MPM relative to that in HDs. The expression level of miR-16- 5p decreased when compared with that of HDs, and the expression levels of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p increased when compared with that of HDs. The sensitivity and specificity values of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p for discriminating MPM from HDs were 85.9% and 59.1%, 95.1% and 62.5%, 87.1% and 79.2%, 82.2% and 58.3%, and 69.3% and 82.6%, respectively. After adjusting for the histological subtype, stage, and treatment, the miR-29c-3p, miR-125a-5p, and miR-484 were associated with longer survival. The miRNA expression levels did not change longitudinally for the determination of chemotherapy response and recurrence. Conclusion: miRNAs may be useful in diagnosing patients with MPM and provides helpful information in determining the prognosis of patients.

🔖

Cite This Article

METİNTAŞ, M., AK, G., BOĞAR, F., METİNTAŞ, S., ÖZBAYER, C. (2022). Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma. Balkan Medical Journal, Cilt: 39 - Sayı: 4, 246–254. https://ajindex.com/articles/648957

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716-724. [CrossRef] Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global asbestos disaster. Int J Environ Res Public Health. 2018;15:1000. [CrossRef] Metintaş S, Batırel HF, Bayram H, et al. Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program. Int J Environ Res Public Health. 2017;14:1293. [CrossRef] Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1-i30. [CrossRef] Ak G, Metintas S, Metintas M, et al. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol. 2009;4:1425-1430. [CrossRef] Vogl M, Rosenmayr A, Bohanes T, et al. Biomarkers for malignant pleural mesothelioma-a novel view on inflammation. Cancers (Basel). 2021;13:658. [CrossRef] Sturchio E, Berardinelli MG, Boccia P, Zanellato M, Gioiosa S. MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma. Arch Environ Occup Health. 2020;75:471-482. [CrossRef] Lo Russo G, Tessari A, Capece M, et al. MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: A literature review. Front Oncol. 2018;8:650. [CrossRef] Kavitha N, Vijayarathna S, Jothy SL, et al. MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev. 2014;15:7489-7497. [CrossRef] Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med. 2015;9:131-151. [CrossRef] Truini A, Coco S, Genova C, et al. Prognostic and therapeutic implications of microRNA in malignant pleural mesothelioma. Microrna. 2016;5:12-18. [CrossRef] Ak G, Tomaszek SC, Kosari F, et al. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. 2015;2015:635748. [CrossRef] Mozzoni P, Ampollini L, Goldoni M, et al. MicroRNA expression in malignant pleural mesothelioma and asbestosis: A pilot study. Dis Markers. 2017;2017:9645940. [CrossRef] Schelch K, Kirschner MB, Williams M, et al. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Mol Oncol. 2018;12:58-